Cartesian Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Cartesian Therapeutics, Inc. (RNAC) reported Debt Securities, Available-for-sale, Unrealized Loss of $100.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2018-05-09
- Cartesian Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2018-03-31 was $100.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month |
|---|---|
| 2018-03-31 | $100.00K 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |